14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CNMD vs AVNS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNMD carries a Unified Composite Score of 37.0/100 (SELL) at $49.39 (10.7x Forward P/E, 10.2% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin).
Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. CNMD 37.0/100 SELL), CNMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. 5.4% operating margin) and revenue trajectory (-0.7% vs. +8.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNMD vs AVNS. Trailing 12-month operating profitability (CNMD 10.2% vs AVNS 5.4%) and valuation multiples (CNMD 10.7x vs AVNS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment44.6% of Rev ($319M)
90D Engineering Disclosures0 Published
Investor FAQ CNMD vs AVNS Key Questions & Quantitative Answers
As of Nov 16, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNMD carries a Unified Composite Score of 37.0/100 (SELL) at $49.39 (10.7x Forward P/E, 10.2% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin). Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. CNMD 37.0/100 SELL), CNMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. 5.4% operating margin) and revenue trajectory (-0.7% vs. +8.8% YoY).
CNMD leads the Growth & Scale pillar: CNMD posts -0.7% YoY revenue growth and +633.3% YoY earnings growth on $1.37B TTM revenue (54.8% gross margin, 10.2% operating margin), compared with AVNS at +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin). On trailing 12-month operating scale, CNMD generates $1.37B in USD-normalized revenue versus $716M for AVNS. In operating R&D and SG&A reinvestment, CNMD deploys 44.6% of Rev ($611M) (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($319M) (0 disclosures) for AVNS.
CNMD screens cheaper on headline valuation multiples. CNMD trades at 10.7x Forward P/E, 20.9x Trailing P/E, 1.84x PEG, and 1.7x EV/Revenue (9.7% FCF margin), whereas AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNMD (7.1% ROE) versus AVNS (-9.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CNMD carries 74.5% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 61% Vol realized risk). By comparison, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.